Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT: Cetuximab with Docetaxel or Pemetrexed in NSCLC
NCT00095199Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2005
- Primary completion
- Jul 2011
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of KL-140 in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Jan 2005; status: completed.
02
Drugs
KL-140
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00095199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00095199.